Global Central Nervous System Partnering 2023: Information on Every Deal Since 2016 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Central Nervous System Partnering 2016-2023: Deal trends, players and financials” report has been added to ResearchAndMarkets.com’s offering.

Global Central Nervous System Partnering 2016 to 2010 provides the full collection of central nervous system disease deals signed between the world’s pharmaceutical and biotechnology companies since 2016.

• Trends in central nervous system partnering deals
• Financial deal terms for headline, upfront and royalty by stage of development
• Central Nervous System partnering agreement structure
• Central Nervous System partnering contract documents
• Top central nervous system deals by value
• Most active central nervous system dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive central nervous system disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering central nervous system deals.

The report presents financial deal terms values for central nervous system deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of central nervous system dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in central nervous system dealmaking since 2016 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading central nervous system deals since 2016. Deals are listed by headline value. The chapter includes the top 25 most active central nervous system dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to central nervous system deals since 2016 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all central nervous system partnering deals by specific central nervous system target announced since 2016. The chapter is organized by specific central nervous system therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all central nervous system partnering deals signed and announced since 2016. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in central nervous system partnering and dealmaking since 2016.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of central nervous system technologies and products.

Report scope

Global Central Nervous System Partnering 2016 to 2023 is intended to provide the reader with an in-depth understanding and access to central nervous system trends and structure of deals entered into by leading companies worldwide.

Global Central Nervous System Partnering 2016 to 2023 includes:

• Trends in central nervous system dealmaking in the biopharma industry since 2016
• Access to headline, upfront, milestone and royalty data
• Access to hundreds of central nervous system deal contract documents
• Comprehensive access to over 1,700 central nervous system deal records
• The leading central nervous system deals by value since 2016
• Most active central nervous system dealmakers since 2016

The report includes deals for the following indications: Cerebral palsy, Creutzfeldt Jakob disease, Dizziness, Epilepsy, Faints, Falls, Guillain Barre syndrome, Headache, Meningitis (Bacterial, Meningococcal, Pneumococcal), Mycobacterium tuberculosis (TB), Haemophilus influenzae Type B (Hib), Migraine, Motor Neurone Disease (Amyotrophic Lateral Sclerosis/Lou Gehrig’s Disease, Multiple sclerosis, Nausea, Neuropathy, Pain, Neuralgia, Fibromyalgia, Paralysis, Parkinson’s disease, Restless leg syndrome, Spinal cord, Stroke, Stuttering, Traumatic Brain Injury, Vertigo, Weakness, plus other CNS indications.

In Global Central Nervous System Partnering 2016 to 2023, available deals and contracts are listed by:

• Headline value
• Upfront payment value
• Royalty rate value
• Stage of development at signing
• Deal component type
• Technology type
• Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Central Nervous System Partnering 2016-2023 report provides comprehensive access to available deals and contract documents for over 1,700 central nervous system deals.

A Selection of Companies Mentioned

• 1ST Biotherapeutics
• 2M
• 3M Drug Delivery Systems
• 3PrimeDx
• 3SBio
• 4SC Discovery
• 7D Surgical
• 23andMe
• A&B Company
• A*STAR Agency for Science
• Technology and Research
• Aarhus University Hospital
• Abbott Laboratories
• Abbvie
• AbCellera
• Abeona Therapeutics
• Abide Therapeutics
• Ablynx
• Ab Medica
• Abzena
• ACADIA Pharmaceuticals
• Accelerated Cure Project for MS
• Accelovance
• Accera Pharmaceuticals
• Acella Pharmaceuticals
• Acerus
• Acetylon Pharmaceuticals
• AC Immune
• Acorda Therapeutics
• Actavis (acquired by Watson)
• Actelion
• Acticor Biotech
• Acturum Life
• Acura Pharmaceuticals
• AcuraStem
• AdAlta
• Adamas Pharmaceuticals
• Adaptive Health
• Adare Pharmaceuticals
• Addex Therapeutics
• Adept Neuro
• Advanced Cooling Therapy
• Advanced Technologies Solutions
• Advantage Consumer Healthcare
• Adventus Ventures
• Aeon Bioscience
• Aequus Pharmaceuticals
• Aeromics
• AEterna Zentaris
• Aethlon Medical
• Affilogic
• AFFiRiS
• Afraxis
• AFT Pharmaceuticals
• AgeX Therapeutics
• Agilent Technologies
• Agilis Biotherapeutics
• Aguettant
• Aiforia Technologies
• AiPing Pharmaceutical
• AirWare Labs
• AKC Canine Health Foundation
• Akorn
• Akrimax Pharmaceutical
• Albany Molecular Research
• Alberta Health Services
• Albert Einstein College of Medicine
• Alcyone Lifesciences
• Alder Biopharmaceuticals
• Alector
• Aleva Neurotherapeutics
• Alexion Pharmaceuticals
• Alfa Wassermann
• AliveGen
• Alkahest
• Alkermes
• Allen Institute for Brain Science
• Allergan
• Allergan (name changed from Actavis)
• Allied Healthcare Products
• Alnylam Pharmaceuticals
• ALS Association
• Alseres Pharmaceuticals
• ALS Finding a Cure Foundation
• Altair
• Altus Formulation
• AlzeCure Pharma
• Alzheimer’s Association
• Alzheimer’s Drug Discovery Foundation
• Alzheimers Research UK
• Amarantus BioSciences
• Ambu
• Amedica
• Amendia
• American Academy of Neurology
• American Association of Neuromuscular & Electrodiagnostic Medicine
• American College of Emergency Physicians
• American College of Physicians Foundation
• American Heart/Stroke Association
• American Heart Association
• American Migraine Foundation
• American National Multiple Sclerosis Society
• American Parkinson Diseases Association
• American Speech-Language-Hearing Association
• Amgen
• Amicus Therapeutics
• Amneal Pharmaceuticals
• AmorChem
• Amydis Diagnostics
• Amylgen
• AnaBios
• Analytical Testing Laboratory
• Anavex Life Sciences
• ANI Pharmaceuticals
• Annette Funicello Research Fund for Neurological Diseases (AFRFND)
• Annovis Bio
• AnthroTronix
• Antibe Therapeutics
• Antidote
• Aphios
• ApiFix
• Appello Pharmaceuticals
• AppliedVR
• APR Applied Pharma Research
• APRINOIA Therapeutics
• Aptahem
• Aptinyx
• Aquinnah Pharmaceuticals
• Aralez Pharmaceuticals
• Aratana Therapeutics
• arGEN-X
• Arizona State University
• ArmaGen
• Array Biopharma
• Arteaus Therapeutics
• Artelo Biosciences
• Arterys
• Arvelle Therapeutics
• Asahi Kasei
• Asana Biosciences
• Ascend Therapeutics
• Asceneuron
• AskAt
• Asklepios Biopharmaceutical
• Aspen Holding
• Assertio Therapeutics
• Association for Frontotemporal Degeneration
• Astellas Pharma
• Astellas Pharma Europe
• Asterias Biotherapeutics
• Astex Pharmaceuticals
• AstraZeneca
• ATAI Life Sciences
• Atara Biotherapeutics
• Ataxion
• Athersys
• Atnahs Pharma
• Aucta Pharmaceuticals
• Aural Analytics
• Aurora Cannabis
• Austin Health
• Australian Imaging
• Biomarker & Lifestyle Flagship Study of Ageing (AIBL)
• Australian Research Council
• Avanos Medical
• Avella
• Avenue Therapeutics
• AveXis
• AXIM Biotechnologies
• AxoSim
• Axovant Sciences
• Axsome Therapeutics
• Axxess Pharma
• Aziyo Biologics
• Bachem
• Bachmann-Strauss Dystonia & Parkinson Foundation
• Baergic Bio
• Bain Capital
• Banyan Biomarkers
• Baudry Laboratory
• Baxter International
• Bayer
• Baylor College
• Baylor College of Medicine
• B Braun
• BD Consultancy
• Becton Dickinson
• Beijing Leadman Biochemistry
• Ben-Gurion University
• BenevolentAI
• Benvenue Medical
• Berg
• Best Choice
• Beyond Batten Disease Foundation
• Bhang
• Bial
• BIA Separations
• Biedermann Motech
• Bio-Techne
• BioArctic Neuroscience
• biOasis Technologies
• BioAxone Therapeutic
• Biocodex
• BIOCORP
• BioCrossroads
• Biodextris
• Biodirection
• Biofourmis
• Biogen
• Biohaven Pharmaceutical Holding
• Biohealth Innovation
• Bioinn Molecular Diagnosis
• BioLamina
• BiolineRX
• BioMarin Pharmaceutical
• Biomedical Advanced Research and Development Authority
• BioMedical Research
• BioMed X Innovation Center
• BioMotiv
• Bionik Laboratories
• Bionomics
• Bionure
• Biopharmaceuticals Australia
• BioQ Pharma
• Bioscience Pharma Partners
• BioSpring
• BioSyent Pharma
• BioTie Therapies
• Biotoscana Farma
• Biscayne Neurotherapeutics
• Blackfynn
• Blackrock Microsystems
• Blackrock NeuroMed
• BlackThorn Therapeutics
• Blinktbi
• Bloom Science
• BlueRock Therapeutics
• Boehringer Ingelheim
• Boston Scientific
• Boston University
• Boston University School of Medicine
• Bpifrance
• Bracket
• Braeburn Pharmaceuticals
• Brain and Spine Institute
• BRAINBox Solutions
• BRAIN Initiative
• BrainLAB
• BrainScope
• BrainStorm Cell Therapeutics
• Brainsway
• Brain Treatment Center San Diego
• Brammer Bio
• Breathe Active
• BridgeBio Pharma
• Brigham and Women’s Hospital
• Bristol-Myers Squibb
• Broad Institute
• Brooks Automation
• Brown University
• Bruker
• C2N Diagnostics
• C4 Therapeutics
• C4X Discovery
• Cactus Semiconductor
• Cadence Biomedical
• Cadence Pharmaceuticals
• Cadila Pharmaceuticals
• Cal-BRAIN
• Calico
• California Institute for Biomedical Research
• California Institute for Regenerative Medicine
• California Institute of Technology
• Calmare Therapeutics
• Calox de Costa Rica
• Camargo Pharmaceutical Services
• Camarus
• Cambridge Cognition
• Cambridge Commodities
• Camino Partnership
• CAMP4 Therapeutics
• Canadian Institutes of Health Research
• Canadian Physiotherapy Association
• Canbex Therapeutics
• Canigma
• CannaKids
• CannaRoyalty
• Canntab Therapeutics
• Cannvalate
• Canon Virginia
• Canopy Growth
• Cantabio Pharmaceuticals
• Capnia
• Caprion Proteomics
• Caputron Medical
• Caraway Therapeutics
• Cardiff University
• Carestream Health
• Caretta Therapeutics
• Carl Zeiss
• Carmot Therapeutics
• Carna BioSciences
• Carnegie Mellon University
• Carrum Health
• Case Western Reserve University
• Casma Therapeutics
• CAS Medical Systems
• Castle Creek Pharmaceuticals
• Catalent
• Catalyst Pharmaceutical Partners
• CavoGene LifeSciences
• CBD Solutions
• Cedars-Sinai Medical Center

For more information about this report visit https://www.researchandmarkets.com/r/sjofb7

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900